Wt1-origin HLA-DR-binding antigen peptide

Abstract

The present invention provides a WT1-derived HLA-DRB1*0405-binding antigen peptide, a polynucleotide encoding said peptide, a helper T cell inducer comprising said peptide or polynucleotide, and the like. It is related to a partial peptide consisting of 10 - 25 contiguous amino acids in the amino acid sequence of human WT1 shown in SEQ ID NO: 1, which binds to HLA-DRB1*0405 and induces helper T cells, a polynucleotide encoding said peptide, or a helper T cell inducer comprising said peptide or polynucleotide.

Description

technical field

[0001] The present invention relates to WT1 derived HLA-DRB1 ＊ 0405 - Conjugated antigenic peptide. Background technique

[0002] The WT1 gene (Wilms' tumor gene 1) has been identified as one of the causative genes of Wilms' tumor, ie, pediatric renal tumor (Cell 60:509, 1990, Nature 343:774, 1990). The WT1 gene encodes the transcription factor WT1, which plays an important role in many processes such as cell proliferation, differentiation, apoptosis and tissue development (Int. Rev. Cytol. 181: 151, 1998). Originally the WT1 gene was described as a tumor suppressor gene. However, follow-up studies revealed that the WT1 gene is highly expressed in leukemia and a variety of solid tumors including lung and breast cancers, indicating that the WT1 gene more precisely plays an oncogenic role in promoting cancer growth. In addition, it was demonstrated that when HLA-A was stimulated in vitro with a WT1-derived peptide ＊ 0201 or HLA-A ＊ 2402-positive peripheral...

Images